Novel treatment options for inflammatory bowel disease: Targeting α4 integrin

Medicine and Dentistry

• Inflammatory Bowel Disease 100%
• Integrin 100%
• Natalizumab 100%
• Treatment Option 100%
• Crohn's Disease 57%
• Progressive Multifocal Leukoencephalopathy 42%
• Monoclonal Antibody 42%
• Lymphocyte 28%
• Randomized Controlled Trial 14%
• Quality of Life 14%
• Endothelial Cell 14%
• Multiple Sclerosis 14%
• Clinical Trial 14%
• Chronic Inflammation 14%
• Immunosuppressive Treatment 14%
• Infusion 14%
• Ulcerative Colitis 14%
• Lymphocytic Infiltration 14%
• Virus Infection 14%
• Microvessel 14%
• Immunopathology 14%
• Patient with Crohn's Disease 14%
• Phase III Trials 14%
• Spontaneous Remission 14%
• Addressin 14%
• Cell Adhesion Molecule 1 14%
• JC Virus 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Inflammatory Bowel Disease 100%
• Integrin 100%
• Natalizumab 100%
• Crohn's Disease 71%
• Remission 57%
• Monoclonal Antibody 42%
• Progressive Multifocal Leukoencephalopathy 42%
• Clinical Trial 14%
• Multiple Sclerosis 14%
• Randomized Controlled Trial 14%
• Ulcerative Colitis 14%
• Virus Infection 14%
• Chronic Inflammation 14%
• Immunopathology 14%
• Phase III Trials 14%
• Lymphocytic Infiltration 14%
• Cell Adhesion Molecule 1 14%
• Addressin 14%

Immunology and Microbiology

• Inflammatory Bowel Disease 100%
• Integrin 100%
• Natalizumab 100%
• Crohn's Disease 71%
• Monoclonal Antibody 42%
• Lymphocyte 42%
• Intestine 28%
• Immunosuppression 14%
• Multiple Sclerosis 14%
• Ulcerative Colitis 14%
• Viral Disease 14%
• Microvasculature 14%
• Immunopathology 14%
• Cell Adhesion Molecule 1 14%
• JC Virus 14%